• Naver’s venture arm D2SF invested in precision medicine startup ImpriMed, taking a minority stake in a USD 10 million Series A2 bridge round.
• Funding targets ImpriMed’s U.S. commercialization in AI-driven precision oncology, with expansion plans into Asia.
• ImpriMed is preparing FDA clearance and CLIA certification by Q1 2027 for an initial U.S. launch.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Naver Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: CN51319) on September 18, 2026, and is solely responsible for the information contained therein.